Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax’ COVID-19 Vaccine in Adolescents ≥12 to <18 in India
First authorization of Novavax’ COVID-19 vaccine in adolescent population received Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorized for adolescents ≥12 to <18 in India Authorization highlights immunogenicity and reassuring safety profile of Covovax in Phase 2/3 study of Indian adolescents aged ≥12 to <18 and data from […]
